Local Tumor Control and Normal Tissue Toxicity of Pulsed Low-Dose-Rate Radiation Therapy (PLRT) for Recurrent Lung Cancer: An In Vivo Study

Zhang, P.; Wang, B.; Chen, X.; Cvetković, D; Chen, L.; Lang, Jinyi; Ma, C

doi:10.1016/j.ijrobp.2014.05.2278

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Damage repair is more likely to occur during low-dose-rate irradiation. 10,13,14,28,29 Most chronic SAEs associated with PLDR-IMRT in this study were less frequent than those associated with IMRT and IMCT in other studies, but fewer acute SAEs were observed in IMCT studies.…”

Section: Discussioncontrasting

confidence: 46%

See 1 more Smart Citation

Efficacy and safety of PLDR‐IMRT for the re‐irradiation of recurrent NPC: A prospective, single‐arm, multicenter trial

Huang

Li²,

Yang

et al. 2023

Cancer Science

View full text Add to dashboard Cite

Salvage treatment of locoregionally recurrent nasopharyngeal carcinoma (NPC) requires weighing the benefits of re-irradiation against increased risks of toxicity. Here, we evaluated the outcomes of patients treated with intensity-modulated-based pulsed low-dose-rate radiotherapy (PLDR-IMRT) to enhance the curative effect of salvage treatment and reduce RT-related SAEs. A prospective clinical trial was conducted from March 2018 to March 2020 at multiple institutions. NPC patients who experienced relapse after radical therapy were re-irradiated with a median dose of 60 Gy (50.4-70 Gy)/30 f (28-35 f) using PLDR-IMRT. Thirty-six NPC patients who underwent PLDR-IMRT for locoregional recurrence were identified. With a median follow-up of 26.2 months, the objective response rate (ORR) of the entire cohort was 91.6%. The estimated mPFS duration was 28 months (95% CI: 24.9-31.1), and the estimated mLRFS duration was 30.4 months (95% CI: 25.2-35.5). The overall survival (OS) rate for all patients was 80.6%, the progression-free survival (PFS) rate was 75% and the cancer-specific survival (CSS) rate was 88.9% at 1 year. The LRFS and DMFS rates were 88.9% and 91.7%, respectively, at 1 year. A combination of systematic therapies could provide survival benefits to patients who experience NPC relapse (p < 0.05), and a Karnofsky performance status (KPS) score of ≥90 was a favorable factor for local control (p < 0.05). The incidence of acute SAEs (grade 3+) from PLDR was 22.2%, and the incidence of chronic SAEs was 19.4% among all patients. PLDR-IMRT combined with systematic therapy can effectively treat patients with locoregionally recurrent nasopharyngeal carcinoma and causes fewer adverse events than the rates expected with IMRT.

show abstract

Section: Discussioncontrasting

confidence: 46%

“…The HRS/IRR phenomenon is associated with the rapid repair of G2 phase cell damage induced by radiation, mainly affecting the early response, while the α/β value of the late response is reduced. Damage repair is more likely to occur during low‐dose‐rate irradiation 10,13,14,28,29 …”

Section: Discussionmentioning

confidence: 99%